13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
38 檔
28.9%
According to the latest 13F quarterly dataset, Prosight Management, LP managed an equity portfolio of $580.4M at the end of Q4 2025, spanning 38 distinct U.S. exchange-listed positions.
In Q4 2025, Prosight Management, LP adopted a defensive or profit-taking posture, trimming 16 positions and completely liquidating 15 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRCT | Procept Biorobotics CORP | Stock-Other | 8.97% | -6.94% | +1692.42% | |
| 2 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 7.26% | +2.93% | -6.60% | |
| 3 | JANX | Janux Therapeutics Inc | Stock-Other | 6.82% | +1.98% | +176.48% | |
| 4 | ✓ | Adc Therapeutics SA | Stock-Other | 6.18% | -3.66% | +13.45% | |
| 5 | KURA | Kura Oncology Inc | Stock-Other | 5.43% | -0.66% | -8.30% | |
| 6 | MGTX | MeiraGTx Holdings plc | Stock-Other | 5.27% | -3.52% | -21.51% | |
| 7 | NKTR | Nektar Therapeutics | Stock-Other | 4.85% | +1.07% | — | |
| 8 | VEEV | Veeva Systems Inc-class A | Stock-Healthcare | 4.16% | +0.76% | — | |
| 9 | ICLR | ICON Public Limited Company | Stock-Healthcare | 4.14% | — | +0.46% | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.14% | +1.15% | +175.95% | |
| 11 | CON | Concentra Group Holdings Par | Stock-Other | 3.62% | -1.78% | EXIT | |
| 12 | PHR | Phreesia Inc | Stock-Other | 3.42% | -1.51% | EXIT | |
| 13 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.38% | — | -32.73% | |
| 14 | SEM | Select Medical Holdings CORP | Stock-Other | 3.18% | — | +18.31% | |
| 15 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.89% | +1.57% | -33.73% | |
| 16 | ZYME | Zymeworks Inc | Stock-Other | 2.89% | +0.83% | -29.24% | |
| 17 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 2.81% | -0.82% | EXIT | |
| 18 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.53% | +0.34% | -20.01% | |
| 19 | AVTR | Avantor Inc | Stock-Healthcare | 2.13% | — | — | |
| 20 | STTK | Shattuck Labs Inc | Stock-Other | 1.80% | +1.84% | -56.31% | |
| 21 | LH | Labcorp Holdings Inc | Stock-Healthcare | 1.79% | — | — | |
| 22 | WGS | Genedx Holdings CORP | Stock-Other | 1.48% | -4.50% | — | |
| 23 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.41% | +0.97% | — | |
| 24 | IMVT | Immunovant Inc | Stock-Other | 1.28% | -0.72% | EXIT | |
| 25 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.15% | -0.02% | +99.15% | |
| 26 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.01% | -0.16% | -38.04% | |
| 27 | CDNA | Caredx Inc | Stock-Other | 0.97% | — | -50.40% | |
| 28 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.79% | -1.75% | EXIT | |
| 29 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.54% | +0.01% | -41.33% | |
| 30 | KIDS | Orthopediatrics CORP | Stock-Other | 0.50% | -0.27% | -55.71% | |
| 31 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.49% | -0.69% | +204.86% | |
| 32 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.47% | — | -88.66% | |
| 33 | ABVX | Abivax Sa-adr | Stock-Other | 0.47% | +0.55% | — | |
| 34 | ACET | Adicet Bio Inc | Stock-Other | 0.44% | -0.28% | EXIT | |
| 35 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 0.43% | — | — | |
| 36 | TBI | Trueblue Inc | Stock-Other | 0.42% | -0.16% | EXIT | |
| 37 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.39% | -0.07% | +7493.81% | |
| 38 | RNTX | Rein Therapeutics Inc | Stock-Other | 0.11% | +0.11% | -22.06% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRCT | Procept Biorobotics CORP | +8.3% | +1692.42% | Add |
| 2 | BSX | Boston Scientific CORP | +2.4% | +175.95% | Add |
| 3 | JANX | Janux Therapeutics Inc | +1.9% | +176.48% | Add |
| 4 | CON | Concentra Group Holdings Par | +0.6% | +46.07% | Add |
| 5 | SEM | Select Medical Holdings CORP | +0.6% | +18.31% | Add |
| 6 | PLRX | Pliant Therapeutics Inc | +0.4% | +7493.81% | Add |
| 7 | OKUR | Onkure Therapeutics Inc-a | +0.3% | +204.86% | Add |
| 8 | TBI | Trueblue Inc | +0.3% | +456.84% | Add |
| 9 | AM6 | Amicus Therapeutics Inc | +0.2% | -32.73% | Trim |
| 10 | CRBP | Corbus Pharmaceuticals Holdi | +0.1% | +99.15% | Add |
| 11 | RNTX | Rein Therapeutics Inc | 0% | -22.06% | Trim |
| 12 | ZYME | Zymeworks Inc | -0.1% | -29.24% | Trim |
| 13 | KURA | Kura Oncology Inc | -0.3% | -8.30% | Trim |
| 14 | ICLR | ICON Public Limited Company | -0.3% | +0.46% | Add |
| 15 | TECX | Tectonic Therapeutic Inc | -0.4% | -38.04% | Trim |
| 16 | RCKT | Rocket Pharmaceuticals Inc | -0.4% | -41.33% | Trim |
| 17 | CRNX | Crinetics Pharmaceuticals In | -0.7% | -20.01% | Trim |
| 18 | SNDX | Syndax Pharmaceuticals Inc | -0.7% | -33.73% | Trim |
| 19 | CDNA | Caredx Inc | -0.7% | -50.40% | Trim |
| 20 | ✓ | Adc Therapeutics SA | -0.8% | +13.45% | Add |
| 21 | KIDS | Orthopediatrics CORP | -0.8% | -55.71% | Trim |
| 22 | STTK | Shattuck Labs Inc | -1.2% | -56.31% | Trim |
| 23 | IMVT | Immunovant Inc | -1.4% | -65.15% | Trim |
| 24 | ROIV | Roivant Sciences Ltd. | -1.9% | -53.04% | Trim |
| 25 | LKFT | Lakefront Biotherapeutic-adr | -2% | -6.60% | Trim |
| 26 | MGTX | MeiraGTx Holdings plc | -2.6% | -21.51% | Trim |
| 27 | BBIO | Bridgebio Pharma Inc | -2.7% | -88.66% | Trim |
| 28 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 29 | ISRG | Intuitive Surgical Inc | — | EXIT | Sold out |
| 30 | VEEV | Veeva Systems Inc-class A | — | NEW | New buy |
| 31 | PHR | Phreesia Inc | — | NEW | New buy |
| 32 | DXCM | Dexcom Inc | — | EXIT | Sold out |
| 33 | ✓ | Corcept Therapeutics Inc | — | EXIT | Sold out |
| 34 | AVTR | Avantor Inc | — | NEW | New buy |
| 35 | BHVN | Biohaven Ltd. | — | EXIT | Sold out |
| 36 | LH | Labcorp Holdings Inc | — | NEW | New buy |
| 37 | VRTX | Vertex Pharmaceuticals Inc | — | EXIT | Sold out |
| 38 | WGS | Genedx Holdings CORP | — | NEW | New buy |
| 39 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 40 | ACHC | Acadia Healthcare Co Inc | — | EXIT | Sold out |
| 41 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 42 | ALGN | Align Technology Inc | — | EXIT | Sold out |
| 43 | ARGX | Argenx Se - Adr | — | EXIT | Sold out |
| 44 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 45 | TWST | Twist Bioscience CORP | — | EXIT | Sold out |
| 46 | ACET | Adicet Bio Inc | — | NEW | New buy |
| 47 | TEM | Tempus Ai Inc-cl A | — | NEW | New buy |
| 48 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 49 | CTMX | Cytomx Therapeutics Inc | — | EXIT | Sold out |
| 50 | SGHT | Sight Sciences Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 38 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRCT, LKFT, JANX) accounted for 28.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
NKTR
市值: $23.4M
Top Position Liquidated / Trimmed
ISRG
前期市值: $21.8M
During Q4 2025, Prosight Management, LP's top holdings by market value included PRCT (9.0%)、LKFT (7.3%)、JANX (6.8%). The largest single position, PRCT, represented 9.0% of total portfolio value.
In Q4 2025, Prosight Management, LP made 53 total portfolio adjustments, initiating 11 new buys, adding to 11 positions, trimming 16 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.